Compare Global X Copper Miners ETF (COPX) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X Copper Miners ETF trades at $85 (market cap $7.10B), while Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M). The key difference: Global X Copper Miners ETF is far larger — about 521.3× Citius Pharmaceuticals Inc's market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Citius Pharmaceuticals Inc for 16 Days on average.
| COPX | CTXR | |
|---|---|---|
Market Cap | $7.10B | $13.62M |
Volume | 2,871,128 | 132,438 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $1.82 |
52-Week Low | $57.43 | $0.48 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | — | $3.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.
The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
